| Date Filed | Type | Description |
| 01/29/2021 |
SC 13G/A
| Tekla Capital Management LLC reports a 0% stake in Zyla Life Sciences |
| 06/01/2020 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 05/22/2020 |
SC 13D/A
| Capital Royalty L.P. reports a 0% stake in Zyla Life Sciences |
| 05/20/2020 |
8-K
| Investor presentation|
Docs:
|
"Assertio Completed Merger with Zyla Life Sciences Trading under ASRT on Nasdaq Global Select Market Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Upwards of $40 million in Expected Cost Synergies LAKE FOREST, Ill., -- Assertio Holdings, Inc., the successor issuer to Assertio Therapeutics, Inc., announced the closing of the merger with Zyla Life Sciences. The combined company will operate under the Assertio name and trade on Nasdaq under the ticker ASRT. The merger creates a growing commercial pharmaceutical company with neurology, inflammation and pain products. The Company now has a differentiated portfolio of non-steroidal anti-inflammatory drugs commonly used by neurologists, orthopedic surgeons, internists, women’ s health providers, podiatrists, p...",
"Presentation by Assertio Holdings, Inc." |
|
| 05/20/2020 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...|
Docs:
|
"Agreement and Plan of Merger, by and among Zyla Life Sciences, Alligator Zebra Holdings, Inc., Assertio Therapeutics, Inc., Zebra Merger Sub, Inc. and Alligator Merger Sub, Inc. (Certain schedules (or similar attachments) to the Agreement and Plan of Merger have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish copies of any such schedules (or similar attachments) to the U.S. Securities and Exchange Commission or its staff upon request.)",
"Fifth Amended and Restated Certificate of Incorporation of Zyla Life Sciences",
"Third Amended and Restated Bylaws of Zyla Life Sciences" |
|
| 05/20/2020 |
25
| Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities: |
| 05/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/15/2020 |
8-K
| Quarterly results |
| 05/15/2020 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/15/2020 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/15/2020 |
8-K
| Quarterly results |
| 05/14/2020 |
10-Q
| Quarterly Report for the period ended March 31, 2020 |
| 05/01/2020 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2020 |
10-K/A
| Annual Report for the period ended December 31, 2019 [amend] |
| 04/20/2020 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/13/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/13/2020 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/27/2020 |
8-K
| Quarterly results |
| 03/27/2020 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/27/2020 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/26/2020 |
10-K
| Annual Report for the period ended December 31, 2019 |
| 03/26/2020 |
SC 13D
| DEPOMED INC reports a 51% stake in Zyla Life Sciences |
| 03/17/2020 |
8-K
| Quarterly results |
| 03/17/2020 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2020 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/12/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/28/2020 |
8-K
| Entry into a Material Definitive Agreement, Other Events |
| 01/24/2020 |
SC 13G
| Tekla Capital Management LLC reports a 7% stake in Zyla Life Sciences |
| 01/13/2020 |
8-K
| Investor presentation |
| 12/19/2019 |
8-K
| Quarterly results |
| 11/14/2019 |
10-Q
| Quarterly Report for the period ended September 30, 2019 |
|